Retatrutide, explained: the triple agonist behind 30% weight loss

The 30-second summary

• Retatrutide is a triple agonist: it acts on three receptors (GIP, GLP-1, and glucagon), where semaglutide acts on one and tirzepatide on two.
• In the Phase 3 TRIUMPH-1 trial reported on 21 May 2026, the highest dose produced an average of 28.3% body-weight loss at 80 weeks, rising to about 30.3% (~85 lbs) at 104 weeks for higher-weight participants who continued.
• It is not approved and not available. Retatrutide is in Phase 3 trials; a filing is expected around late 2026 and approval, if it comes, around 2027–2028.

The number everyone is seeing

On 21 May 2026, Eli Lilly released the first Phase 3 results for retatrutide, its triple-agonist weight-loss drug, from a trial called TRIUMPH-1. The headline figure travelled fast: an average of 28.3% of body weight lost at 80 weeks on the highest dose, and up to 30.3%, roughly 85 pounds on average, at 104 weeks for participants who started heavier and stayed on the drug.

To put that in context: semaglutide (Wegovy) averages around 15% in its landmark trial. Tirzepatide (Zepbound) averages around 21% at its top dose. Retatrutide, in this trial, went meaningfully beyond both. It is the largest average weight loss any obesity medication has shown in a Phase 3 trial to date.

That is the news. The more useful question is why, and what it means for a woman who is already on a GLP-1 today.

What a "triple agonist" actually means

Your gut releases hormones after you eat. Three of them matter here:

• GLP-1: slows stomach emptying, signals fullness, dampens appetite.
• GIP: works alongside GLP-1 on insulin and, it appears, on how the brain regulates appetite and fat.
• Glucagon: best known for raising blood sugar, but it also increases the body's energy expenditure and helps mobilise fat from the liver.

The drugs in this class are defined by how many of these receptors they switch on:

• Semaglutide (Ozempic, Wegovy) is a single agonist: GLP-1 only.
• Tirzepatide (Mounjaro, Zepbound) is a dual agonist: GLP-1 + GIP.
• Retatrutide is a triple agonist: GLP-1 + GIP + glucagon.

The glucagon receptor is the new third leg, and it is doing something the other two cannot: rather than only reducing how much you eat, it appears to increase how much energy you burn. That combination, eating less and spending more, is the leading explanation for why the weight-loss numbers stepped up.

It is also why retatrutide raises heart rate slightly more than its predecessors (about 6–7 beats per minute on average in the trials), which is one of the things the Phase 3 program is watching carefully.

What TRIUMPH-1 measured, and what it didn't

TRIUMPH-1 enrolled 2,339 adults with obesity or overweight plus at least one weight-related condition (high blood pressure, abnormal cholesterol, sleep apnoea, or osteoarthritis), and without diabetes. The dose-escalation arm that climbed gently still reached 19.0% loss, with a discontinuation rate lower than placebo, a sign the drug was reasonably tolerated when titrated slowly.

Two honest caveats:

1. This is manufacturer topline data, not a peer-reviewed paper. The full results, including the detail on side effects and body composition, will be published and presented over the coming months. The number is real, but the complete picture always arrives later.
2. A weight number is not a body-composition number. Average weight lost tells you the scale moved. It does not, on its own, tell you how much of that was fat and how much was muscle. That distinction matters enormously, and it is the subject of a separate article in this series.

The status, stated plainly

Retatrutide is investigational. It is in Phase 3 trials. It is not approved by the FDA or any major regulator, and it cannot be prescribed for weight loss today. Industry timelines point to a regulatory filing around late 2026 and a possible approval in the 2027–2028 window, with several more TRIUMPH trials (in diabetes, in cardiovascular disease) reporting through 2026 first.

In other words: this is a preview of where the field is going, not a drug you can ask for at your next appointment. The drug your prescriber can actually offer you today is still semaglutide or tirzepatide, and how you use that is what determines your results this year.

Why the magnitude raises the stakes, not just the hopes

Here is the part that gets lost in the headline. The more weight you lose, the more of your body is in flux, and that includes muscle. Across the GLP-1 class, when no deliberate steps are taken, roughly a quarter to a third of the weight lost is lean mass, not fat. A drug that takes someone from 15% loss to 30% loss does not suspend that math; it operates on a larger total.

This is not an argument against the drugs. It is an argument for using them well. The same two interventions that protect muscle on any GLP-1, enough protein and resistance training, become more important as the weight loss gets larger, not less. The science on that is consistent and not new. (Cermak et al., AJCN 2012.)

What Steady does with this

Steady does not track retatrutide, it is not approved, and the app supports the medications women can actually be prescribed today: Ozempic, Wegovy, Mounjaro, Zepbound, and four more. But the principle that makes Steady useful is exactly the one the retatrutide data underlines: the scale is the least interesting number. What you keep, muscle, energy, hair, steadiness through your cycle, is the real outcome.

If you are on a GLP-1 now, the foundation you build today carries forward to whatever you take next. Steady sets a protein target to protect lean mass, tracks fourteen GLP-1 symptoms on a severity slider, reads your cycle alongside your dose, and turns it all into a one-page picture for your prescriber. When the next generation of these drugs arrives, you will not be starting from zero.

Read next: retatrutide vs tirzepatide vs semaglutide, and what 30% weight loss means for women specifically. For the bigger picture on the drug landscape, see Mounjaro vs Wegovy and why muscle is the number that matters. The full overview lives on our retatrutide page.

Sources

1. Eli Lilly and Company. Retatrutide delivered weight loss of up to an average of 71.2–85 lbs in the Phase 3 TRIUMPH-1 trial (topline results). 21 May 2026. Lilly investor news
2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. NEJM 2023;389:514-526. NEJM
3. Aronne LJ, et al. Tirzepatide vs Semaglutide for Obesity (SURMOUNT-5). NEJM 2025. NEJM
4. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM 2021;384:989-1002. NEJM
5. Cermak NM, et al. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise. AJCN 2012. PubMed

Medical disclaimer: Articles in the Steady research hub are educational, not medical advice. Retatrutide is an investigational drug and is not approved or available by prescription. Do not make decisions about any medication based on this article, talk to your prescriber. See our full medical disclaimer.